Breaking News

Exclusive: Disagreements over Duchenne therapy, management style may have led to FDA official's exit

June 20, 2025
Nicole Verdun, seen here at a National Institutes of Health event in 2024, was serving as director of the office that reviews cell and gene therapies at the Food and Drug Administration, before she was placed on administrative leave.
NIH

STAT+ | Disagreements over Duchenne therapy, management style may have led to ouster of key FDA official

Nicole Verdun's ouster followed a disagreement over review of cell therapy for Duchenne muscular dystrophy, long-simmering tensions over management style.

By Adam Feuerstein, Matthew Herper, Jason Mast, and Lizzy Lawrence


STAT+ | Senate Republicans debate Medicaid options as hospitals move to shape legislation

Senate budget writers, on a tight deadline, try to balance demands for steeper federal funding cuts on one side and fewer cuts to hospitals on the other.

By Daniel Payne and John Wilkerson


STAT+ | As AI device market grows, FDA's accounting goes silent

As the market for AI enabled medical devices grows, experts worry there is less transparency around the agency's device approvals.

By Katie Palmer



STAT

Why MAHA wants whole milk back on the table

In the nutrition world, the question of how whole milk compares with lower-fat options is the subject of debate. In MAHA world, it's time to embrace change.

By Sarah Todd


Opinion: Six former CDC vaccine advisory committee chairs warn: U.S. risks losing access to life-saving immunizations

We are witnessing a dismantling of the systems that develop, license, recommend, and monitor vaccines, according to vaccine experts.

By Grace Lee, Nancy Bennett, Jonathan Temte, Carol Baker, and José Romero


Opinion: The MAHA children's health report mis-cited our research. That's sloppy — and worrying

Two of our papers were cited in the MAHA report as evidence about the dangers of advertising to children — except they weren't.

By Steven Woloshin and Richard L. Kravitz


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Daily Recap? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2025, All Rights Reserved.

No comments